XNAS
PBLA
Market cap0kUSD
Oct 08, Last price
0.00USD
1D
0.00%
1Q
-99.99%
IPO
-100.00%
Name
Panbela Therapeutics Inc
Chart & performance
P/E
—
P/S
—
EPS
—
Div yield, %
—
Shrs. gr., 5y
180.33%
Rev. gr., 5y
%
Revenues
0
Net income
-25m
L-27.68%
CFO
-25m
L+65.29%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Panbela Therapeutics, Inc. is a biopharmaceutical enterprise currently in clinical development, along with its subsidiaries, dedicated to advancing innovative therapies for cancer patients. The company's therapeutic endeavors primarily target pancreatic disorders, including pancreatitis, pancreatic cancer, and neoadjuvant pancreatic cancer. Beyond pancreatic diseases, they are also exploring treatments for colorectal cancer, ovarian cancer, and various other oncology indications. Their flagship experimental drug, SBP-101, is currently undergoing Phase Ia/Ib clinical trials, specifically intended for individuals diagnosed with metastatic pancreatic ductal adenocarcinoma. Established in 2011, the company, headquartered in Waconia, Minnesota, rebranded from its prior name, Sun BioPharma, Inc., to Panbela Therapeutics, Inc. in December 2020.
Key people
Michael T. Cullen
Chairman of the Board, President, Chief Executive Officer · since 2018
Susan Horvath
Chief Financial Officer, Vice President - Finance, Secretary · since 2018
Chief Financial Officer, Vice President - Finance · since 2015
Suzanne Gagnon
Chief Medical Officer, Director · since 2015
Independent Director · since 2015
Paul W. Schaffer
Independent Director · since 2015
Donald Robert Schemel
Independent Director · since 2015
IPO date
Jul 29, 2014
Employees
6
Domiciled in
US
Incorporated in
US
Legal address
C/O Capitol Services, Inc.
108 LAKELAND AVE.
DOVER, DE 19901
US
108 LAKELAND AVE.
DOVER, DE 19901
US
Headquarters
712 Vista Boulevard
Suite 305
Waconia, MN 55387
US
Suite 305
Waconia, MN 55387
US
Previous name
Sun Biopharma, Inc.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||
Revenues | ||||||||
Cost of revenue | ||||||||
Unusual Expense (Income) | ||||||||
NOPBT | ||||||||
NOPBT Margin | ||||||||
Operating Taxes | ||||||||
Tax Rate | ||||||||
NOPAT | ||||||||
Net income | ||||||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | ||||||||
BB yield | ||||||||
| Debt | ||||||||
Debt current | ||||||||
Long-term debt | ||||||||
Deferred revenue | ||||||||
Other long-term liabilities | ||||||||
Net debt | ||||||||
| Cash flow | ||||||||
Cash from operating activities | ||||||||
CAPEX | ||||||||
Cash from investing activities | ||||||||
Cash from financing activities | ||||||||
FCF | ||||||||
| Balance | ||||||||
Cash | ||||||||
Long term investments | ||||||||
Excess cash | ||||||||
Stockholders' equity | ||||||||
Invested Capital | ||||||||
ROIC | ||||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | ||||||||
Price | ||||||||
Market cap | ||||||||
EV | ||||||||
EBITDA | ||||||||
EV/EBITDA | ||||||||
Interest | ||||||||
Interest/NOPBT | ||||||||